CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
21-961

CHEMISTRY REVIEW(S)
Simvastatin
10 mg, 20 mg, 40 mg, 80 mg
Orally Disintegrating Tablets
NDA 21-961

Summary of the Basis for the Recommended Action from Chemistry, Manufacturing, and Controls

Applicant: Synthon Pharmaceuticals, Inc
9000 Development Drive
P.O. Box 110487
Research Triangle Park, North Carolina 27709

Indication: Treatment of hypercholesterolemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, dysbetalipoproteinemia.

Presentation: Orally disintegrating tablet (ODT) containing 10 mg (yellow), 20 mg (peach), 40 mg (pink), or 80 mg (white) of simvastatin for oral administration. The tablets are round, biconvex with the product strength debossed on one side and "ODT" on the other side. The tablets are packaged in bottles: 7 count, 75 ml (professional sample); 30 count, 75 mL; or 90 count, 150 ml.

EER Status: Acceptable 16-MAY-2006

Consults: DMETS – Not Requested by clinical division (HFD-510)
EA – Categorical exclusion granted under 21 CFR §25.31(b)
Methods Validation – Revalidation by Agency not requested

Original Submission: 28-JUL-2005

Post-Approval Agreements:

The applicant agrees to place batch of each strength, in the approved container/closure, annually, in the post-approval stability program, if any batches are manufactured.

The applicant agrees to place the manufacturing process validation batches on stability per the bracketing schedule outlined in Volume 11, Module 3, Section 2.P.8.2, Exhibit 6.

The applicant agrees, in a postmarketing commitment letter of May 18, 2006, to develop a dissolution method and specification to assure characteristics of Simvastatin Orally Disintegrating Tablets.
Drug Substance

Simvastatin is a lipid-lowering agent that is derived synthetically from lovastatin, a fermentation product of Aspergillus terreus. Simvastatin is an inactive lactone that is hydrolyzed, after ingestion, to the corresponding beta-hydroxy acid. This main metabolite of simvastatin inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyses an early step in the biosynthesis of cholesterol, and thereby limits the rate of overall cholesterol biosynthesis.

The chemistry, manufacturing, and controls information for the drug substance is appropriately referenced, is described in Synthon BV's Type II DMF 18384, has been reviewed, and is concluded to be adequate.

Conclusion: Drug substance is acceptable.

Drug Product

The drug product is an orally disintegrating tablet (ODT) containing 10 mg, 20 mg, 40 mg, or 80 mg of simvastatin. The tablets are round, biconvex, with the product strength debossed on one side and "ODT" on the other side. Product strength debossed on tablet for 10 mg (yellow) reads "S10", for 20 mg (peach) reads "S20", 40 mg (pink) reads "S40", and 80 mg (white) reads "S80."

The tablets are formulated with butylated hydroxyanisole, Povidone —— Crospovidone. ——— hydroxypropylcellulose, silicified microcrystalline cellulose, mint menthol sucralose, glyceryl behenate and iron oxide-based colorant.

Specifications for the drug product include: visual description, identification by HPLC, assay by HPLC, purity, impurity and content uniformity by HPLC, antioxidant, residual water content, dissolution and microbial testing. All tests methods have been appropriately validated for their intended purpose. The dissolution data demonstrate that the subject drug and the listed drug are comparable.

Submitted stability data support the proposed storage is at 25°C (room temperature) for ——— is for drug product packaged in the proposed bottle. The label claim for storage will be "Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [See USP]. Avoid exposure to excessive heat or light".

Conclusion: Drug product is satisfactory.
Additional Items:

As the analytical methods used in the testing procedures (release, stability and in-process) are well known and widely used by the pharmaceutical industry, revalidation by Agency laboratories will not be requested.

All associated Drug Master Files are acceptable or the pertinent information has been adequately provided in the application.

Overall Conclusion:

From a CMC perspective, the application is recommended for approval.

Blair A. Fraser, Ph.D.
Branch Chief, Branch II
DPA I/ONDQA
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Blair Fraser
5/19/2006 03:28:51 PM
CHEMIST

Appears This Way
On Original
NDA 21-961

Simvastatin

Synthon

John C. Hill, Ph.D.
ONDQA/DPA I/DMEP/HFD-510

Chemistry Review #4

Appears This Way
On Original
Table of Contents

Table of Contents ........................................................................................................... 2

Chemistry Review Data Sheet ......................................................................................... 3

The Executive Summary ................................................................................................. 7

I. Recommendations ...................................................................................................... 7
   A. Recommendation and Conclusion on Approvability .............................................. 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .............................................. 7

II. Summary of Chemistry Assessments ....................................................................... 7
   A. Description of the Drug Product(s) and Drug Substance(s) ................................. 7
   B. Description of How the Drug Product is Intended to be Used ............................ 9
   C. Basis for Approvability or Not-Approval Recommendation ............................... 10

III. Administrative ......................................................................................................... 10
   A. Reviewer’s Signature ................................................................ ......................... 10
   B. Endorsement Block ......................................................................................... 10
   C. CC Block ..................................................................................................... 10

Chemistry Assessment ................................................................................................. 11

Appears This Way  
On Original
Chemistry Review Data Sheet

1. NDA # 21-961

2. REVIEW # 4


4. REVIEWER: John C. Hill, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original NDA Filing</td>
<td>28-JUL-2005</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>13-OCT-2005</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>03-FEB-2006</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>09-FEB-2006</td>
</tr>
<tr>
<td>BL Amendment</td>
<td>23-FEB-2006</td>
</tr>
<tr>
<td>BM Amendment (DMF Correspondence)</td>
<td>27-MAR-2006</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>16-MAY-2006</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>19-MAY-2006</td>
</tr>
<tr>
<td>BL Amendment</td>
<td>24-MAY-2006</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ Amendment</td>
<td>16-APR-2007</td>
</tr>
<tr>
<td>BZ Amendment</td>
<td>23-MAY-2007</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Synthon Pharmaceuticals, Inc.
Address: 9000 Development Drive
          P.O. Box 110487
          Research Triangle Park, North Carolina 27709

Page 3 of 12
8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name:
   b) Non-Proprietary Name (USAN): Simvastatin
   c) Code Name/# (ONDC only):
   d) Chem. Type/Submission Priority (ONDC only):
      • Chem. Type: 3
      • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(2)
   Listed Drug: Zocor (Merck) NDA #19-766

10. PHARMACOL. CATEGORY: Hypercholesterolemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, dysbetalipoproteinemia.

11. DOSAGE FORM: Tablet

12. STRENGTH/POTENCY: 10, 20, 40, and 80 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED:  _X_Rx     ____OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____SPOTS product – Form Completed
    _X__Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
Name: Simvastatin
Molecular Formula: C_{25}H_{38}O_{3}
Molecular Weight: 418.57

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>18384</td>
<td>II</td>
<td>Synthon BV</td>
<td>Simvastatin API</td>
<td>4</td>
<td>Adequate</td>
<td>08-FEB-2006</td>
<td>LOA 08-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>13-JAN-2006</td>
<td>LOA 27-MAY-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>30-AUG-2005</td>
<td>LOA 11-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>Acceptable as NF</td>
<td>LOA 23-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>21-SEP-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-JAN-2003</td>
<td>LOA 28-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-AUG-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>30-AUG-2001</td>
<td>LOA 27-JUN-2005</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 –
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIND</td>
<td>70,964</td>
<td>Simvastatin Orally Disintegrating Tablets 10 mg, 20 mg, 40 mg, and 80 mg.</td>
</tr>
</tbody>
</table>

18. STATUS:

**ONDC:**

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>17-MAY-2006</td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Acceptable</td>
<td>22-DEC-2005</td>
<td>John C. Hill, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**OGD:**

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only)

The application submission(s) covered by this review was taken in the date order of receipt.  
_____ Yes  
_____ No   If no, explain reason(s) below:

Appears This Way  
On Original
The Chemistry Review for NDA 21-961

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC viewpoint this NDA can be approved (AP). All outstanding CMC issues have been resolved. The pre-approval inspections have been completed and the Office of Compliance recommendation is acceptable.

Based on the provided real-time and accelerated stability data, the proposed expiry period of 18 months is granted.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

The Agency requests that Synthon commit to concurrently validating the more discriminating dissolution method QC.WO.SVT.odt.020.C/12.02 (submitted as a BC amendment dated 15-MAY-2006) to NDA 21-961 while performing Simvastatin lot release testing using dissolution method QC.US01.SVT.020.C/6. The new dissolution test method (QC.WO.SVT.odt.020.C/12.02) will be validated to support a lot release specification of Q— at 15 minutes.

The new dissolution test method (QC.WO.SVT.odt.020.C/12.02) will also be included in the stability protocol. Appropriate real-time and accelerated stability data will be required to support the use of the new dissolution test method instead of the current dissolution test method. These stability data can be updated in the annual report to support the proposed dating period.

Upon validation, Synthon will amend NDA 21-961 to replace lot release dissolution testing method QC.US01.SVT.020.C/6 with the fully validated dissolution method QC.WO.SVT.odt.020.C/12.02.

This amendment is to be submitted within six (6) months of approval of NDA 21-961

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1. Drug Product

The drug product presented in this NDA is an orally disintegrating tablet containing either 10, 20, 40 or 80 mg of simvastatin. The tablets are round, biconvex with the
product strength debossed on one side and "ODT" on the other side. Following is a
detailed description of appearance for each tablet strength.

10 mg Tablets
Yellow, round, biconvex tablets. These tablets are debossed with "S10" on
one side and "ODT" on the other side.

20 mg Tablets
Peach, round, biconvex tablets. These tablets are debossed with "S20" on one
side and "ODT" on the other side.

40 mg Tablets
Pink, round, biconvex tablets. These tablets are debossed with "S40" on one
side and "ODT" on the other side.

80 mg Tablets
White to off-white, round, biconvex tablets. These tablets are debossed with
"S80" on one side and "ODT" on the other side.

The individual components used to manufacture Simvastatin 10 mg, 20 mg, 40 mg
and 80 mg orally disintegrating tablets are listed in the following table.

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Function</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin</td>
<td>lipid altering agent</td>
<td>USP / Ph. Eur.</td>
</tr>
<tr>
<td>Bovine hydronicole</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Povidone</td>
<td></td>
<td>USP</td>
</tr>
<tr>
<td>Crospovidone</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Hydroxypropylcellulose*</td>
<td></td>
<td>USP / NF</td>
</tr>
<tr>
<td>Silicified microcrystalline cellulose*</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Mint menthol*</td>
<td>in house</td>
<td>in house</td>
</tr>
<tr>
<td>Sucrose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide red</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Glyceryl behenate*</td>
<td></td>
<td>NF</td>
</tr>
</tbody>
</table>

Excipients used to manufacture the drug product are of USP/NF quality with the
exception of mint menthol and Silicified microcrystalline cellulose, which are tested
in-house for quality. The drug product is composed of:

During formulation development of the drug product, careful evaluation of excipients,
particle size, and stability were conducted to develop a stable, rapidly
disintegrating tablet. Initial formulation development, conducted with a
simvastatin particle, provided fundamental information about interactions
with excipients, development of a suitable optimization of
parameters, evaluation of tablet size and forces on disintegration and dissolution times. The desire for increased bioavailability of simvastatin resulted in the use of a simvastatin particle. This formulation change required additional optimization of the and the formulations. Additionally, initial stability data indicated that basic excipients used in the formulation of simvastatin on stability resolved this stability issue.

2. Drug Substance:

The drug substance is simvastatin \( [1\alpha,3\alpha,7\beta,8\beta(2S^*,4S^*),8\alpha\beta] \),. The manufacture of this compound is described in DMF# 18384. This DMF contains complete information on the manufacture, control of materials, control of critical steps and intermediates, process validation, manufacturing process development, elucidation of structure, impurities, control of the drug substance, drug substance specifications, analytical procedures, batch analyses, justification of specifications, reference standards and materials, release testing, container closure system, drug substance stability, and stability summary and conclusions.

Simvastatin is a lipid-lowering agent that is derived synthetically from lovastatin, a fermentation product of \textit{Aspergillus terreus}. Simvastatin is an inactive lactone, which is hydrolyzed after ingestion to the corresponding beta-hydroxyacid. This main metabolite of simvastatin inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which catalyses an early step in the biosynthesis of cholesterol, limiting the rate of the total reaction.

Some of the key characteristics of Simvastatin drug substance that may influence the performance of the drug product, and were evaluated during product development include solubility, potential isomerism/polymorphism, exposure to light, alkaline media and oxidation. In order to increase the bioavailability, the simvastatin drug substance was the mean particle size from around to around.

B. Description of How the Drug Product is Intended to be Used

\textbf{Hypercholesterolemia:}

Simvastatin is used to reduce increased plasma total and LDL cholesterol in patients with primary hypercholesterolaemia (type IIa) or combined hyperlipidemia (type IIb) in combination with dietary measures when no adequate effect is obtained with dietary measures and other non-pharmacological measures alone (e.g., fitness training and weight loss).

\textbf{Coronary Heart Disease:}
Simvastatin is used for the secondary prevention of coronary heart disease in patients with elevated plasma cholesterol levels (>5.5 mmol/L). Prophylaxis with simvastatin is indicated if total cholesterol-serum concentration is 5.5 mmol/L (212 mg/dl) or higher, despite lipid-lowering diet and other non-pharmacological measures and should be carried out in conjunction with diet and other non-pharmacological measures (e.g., physical training and weight reduction).

C. Basis for Approvability or Not-Approval Recommendation

This application is approvable (AE) from a CMC viewpoint. This recommendation is based upon the evaluation of the relevant drug product manufacturing, characterization and stability data provided in this 505(b)(2) application. These data are substantial, detailed and acceptable. The applicant has demonstrated lot-to-lot consistency in the manufacture and quality of the drug product. However, certain CMC deficiencies remain be addressed. The CGMP facility inspections are pending.

III. Administrative

A. Reviewer's Signature

B. Endorsement Block

John C. Hill, Ph.D., Review Chemist: Same date as electronic review
Ali Al-Hakim, Ph.D., Branch Chief: Same date as electronic review

C. CC Block

Margaret A Simoneau, RPH, Project Manager: Same date as electronic review

Appears This Way
On Original
2 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

☐ Draft Labeling (b4)

☐ Draft Labeling (b5)

☐ Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
John C. Hill
6/22/2007 11:17:20 AM
CHEMIST

Ali Al-Hakim
6/22/2007 02:30:58 PM
CHEMIST

Appears This Way
On Original
NDA 21-961

Simvastatin

Synthon

John C. Hill, Ph.D.
ONDQA/DPA I/DMEP/HFD-510

Chemistry Review #3

Appears This Way
On Original
# CHEMISTRY REVIEW

## Table of Contents

- **Table of Contents** ................................................................. 2
- **Chemistry Review Data Sheet** .................................................. 3
- **The Executive Summary** .......................................................... 6
- **I. Recommendations** ............................................................. 6
  - A. Recommendation and Conclusion on Approvability ......................... 6
  - B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .......................... 6
- **II. Summary of Chemistry Assessments** ........................................... 6
  - A. Description of the Drug Product(s) and Drug Substance(s) ................. 6
  - B. Description of How the Drug Product is Intended to be Used ............. 8
  - C. Basis for Approvability or Not-Approval Recommendation ............... 8
- **III. Administrative** ............................................................... 8
  - A. Reviewer’s Signature .......................................................... 8
  - B. Endorsement Block ............................................................ 8
  - C. CC Block ........................................................................ 8
- **Chemistry Assessment** .............................................................. 9

*Appears This Way On Original*
Chemistry Review Data Sheet

1. NDA # 21-961
2. REVIEW # 3
3. REVIEW DATE: 17-May-2006
4. REVIEWER: John C. Hill, Ph.D.
5. PREVIOUS DOCUMENTS:

   Previous Documents          Document Date

6. SUBMISSION(S) BEING REVIEWED:

   Submission(s) Reviewed         Document Date
   Original NDA Filing             28-JUL-2005
   BC Amendment                    03-FEB-2006
   BC Amendment                    09-FEB-2006
   BL Amendment                    23-FEB-2006
   Amendment (DMF Correspondence)  27-MAR-2006
   Amendment # 09                  19-MAY-2006

7. NAME & ADDRESS OF APPLICANT:

   Name: Synthon Pharmaceuticals, Inc.
   Address: 9000 Development Drive
             P.O. Box 110487
             Research Triangle Park, North Carolina 27709
   Representative: Kamali Chance, MPH, Ph.D. RAC, Director Regulatory Affairs
   Telephone: 919-493-6066

8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name:
   b) Non-Proprietary Name (USAN): Simvastatin
   c) Code Name/# (ONDC only):
   d) Chem. Type/Submission Priority (ONDC only):
      - Chem. Type: 3
      - Submission Priority: S
9. LEGAL BASIS FOR SUBMISSION: 505(b)(2)
   Listed Drug: Zocor (Merck) NDA #19-766

10. PHARMACOL. CATEGORY: Hypercholesterolemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, dysbetalipoproteinemia.

11. DOSAGE FORM: Tablet

12. STRENGTH/POTENCY: 10, 20, 40, and 80 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED:    X  Rx    OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed    X  Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   Name: Simvastatin
   Molecular Formula: C_{25}H_{36}O_{5}
   Molecular Weight: 418.57

17. RELATED/SUPPORTING DOCUMENTS:

   A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>Type</th>
<th>Holder</th>
<th>Item Referenced</th>
<th>Code¹</th>
<th>Status²</th>
<th>Date Review Completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>18384</td>
<td>II</td>
<td>Synthon BV</td>
<td>Simvastatin API</td>
<td>4</td>
<td>Adequate</td>
<td>08-FEB-2006</td>
<td>LOA 09-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>13-JAN-2006</td>
<td>LOA 27-MAY-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>30-AUG-2005</td>
<td>LOA 11-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable as NF</td>
<td>Acceptable as NF</td>
<td>LOA 23-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>21-SEP-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-JAN-2003</td>
<td>LOA 28-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-AUG-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>30-AUG-2001</td>
<td>LOA 27-JUN-2005</td>
</tr>
</tbody>
</table>

¹ Action codes for DMF Table:
1 – DMF Reviewed.
2 – Other codes indicate why the DMF was not reviewed, as follows:
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:
18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>16-MAY-2006</td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Acceptable</td>
<td>22-DEC-2005</td>
<td>John C. Hill, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 21-961

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC viewpoint this NDA can be approved (AP). All outstanding CMC issues have been resolved. The pre-approval inspections have been completed and the Office of Compliance recommendation is acceptable.

Based on the provided real-time and accelerated stability data, the proposed expiry period of 18 months is granted.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

Synthon agrees (amendment 09, dated May 18, 2006) to concurrently validate the more discriminating dissolution method QC.WO.SVT.odt.020.C/12.02 (submitted as amendment 08 dated 16-MAY-2006) to NDA 21-961 while performing Simvastatin lot release testing using dissolution method QC.US01.SVT.020.C/6. The new dissolution test method (QC.WO.SVT.odt.020.C/12.02) will be validated to support a lot release specification of \( C \) at 15 minutes.

The new dissolution test method (QC.WO.SVT.odt.020.C/12.02) will also be included in the stability protocol. Appropriate real-time and accelerated stability data will be required to support the use of the new dissolution test method instead of the current dissolution test method. These stability data can be updated in the annual report to support the proposed dating period.

Upon validation, Synthon will amend NDA 21-961 to replace lot release dissolution testing method QC.US01.SVT.020.C/6 with the fully validated dissolution method QC.WO.SVT.odt.020.C/12.02.

This amendment is to be submitted within \( b(4) \) of approval of NDA 21-961.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1. Drug Product

The drug product presented in this NDA is an orally disintegrating tablet containing either 10, 20, 40 or 80 mg of simvastatin. The tablets are round, biconvex with the product strength debossed on one side and "ODT" on the other side. Following is a detailed description of appearance for each tablet strength.

10 mg Tablets
Yellow, round, biconvex tablets. These tablets are debossed with "S10" on one side and "ODT" on the other side.

20 mg Tablets
Peach, round, biconvex tablets. These tablets are debossed with "S20" on one side and "ODT" on the other side.
40 mg Tablets
Pink, round, biconvex tablets. These tablets are debossed with "S40" on one side and "ODT" on the other side.

80 mg Tablets
White to off-white, round, biconvex tablets. These tablets are debossed with "S80" on one side and "ODT" on the other side.

The individual components used to manufacture Simvastatin 10 mg, 20 mg, 40 mg and 80 mg orally disintegrating tablets are listed in the following table.

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Function</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin</td>
<td>lipid altering agent</td>
<td>USP / Ph. Eur.</td>
</tr>
<tr>
<td>Butylated hydroxypropylcellulose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Povidone</td>
<td></td>
<td>USP</td>
</tr>
<tr>
<td>Crosscrodione</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>hydroxypropylcellulose*</td>
<td></td>
<td>USP / NF</td>
</tr>
<tr>
<td>Silicified microcrystalline cellulose*</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Mint menthol*</td>
<td></td>
<td>in house</td>
</tr>
<tr>
<td>Sucrose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide red</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Glyceryl behenate*</td>
<td></td>
<td>NF</td>
</tr>
</tbody>
</table>

Excipients used to manufacture the drug product are of USP/NF quality with the exception of mint menthol and Silicified microcrystalline cellulose, which are tested in-house for quality. The drug product is composed of

During formulation development of the drug product, careful evaluation of excipients, particle size, and stability were conducted to develop a stable, rapidly disintegrating tablet. Initial formulation development, conducted with a simvastatin particle, provided fundamental information about interactions with excipients, development of a suitable optimization of parameters, evaluation of tablet size and forces on disintegration and dissolution times. The desire for increased bioavailability of simvastatin resulted in the use of a simvastatin particle. This formulation change required additional optimization of the simvastatin formulations. Additionally, initial stability data indicated that basic excipients used in the formulation resolved this stability issue.

2. Drug Substance:

The drug substance is simvastatin.

The manufacture of this compound is described in DMF# 18384. This DMF contains complete information on the manufacture, control of materials, control of critical steps and intermediates, process validation, manufacturing process development, elucidation of structure, impurities, control of the drug substance, drug substance specifications, analytical procedures, batch analyses, justification of specifications, reference standards and materials, release testing, container closure system, drug substance stability, and stability summary and conclusions.
Simvastatin is a lipid-lowering agent that is derived synthetically from lovastatin, a fermentation product of *Aspergillus terreus*. Simvastatin is an inactive lactone, which is hydrolyzed after ingestion to the corresponding beta-hydroxyacid. This main metabolite of simvastatin inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which catalyses an early step in the biosynthesis of cholesterol, limiting the rate of the total reaction.

Some of the key characteristics of Simvastatin drug substance that may influence the performance of the drug product, and were evaluated during product development include solubility, potential isomerism/polymorphism, exposure to light, alkaline media and oxidation. In order to increase the bioavailability, the simvastatin drug substance was ground to around 80% of the mean particle size from 200 μm.

B. Description of How the Drug Product is Intended to be Used

Hypercholesterolemia:

Simvastatin is used to reduce increased plasma total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) or combined hyperlipidemia (type IIb) in combination with dietary measures when no adequate effect is obtained with dietary measures and other non-pharmacological measures alone (e.g., fitness training and weight loss).

Coronary Heart Disease:

Simvastatin is used for the secondary prevention of coronary heart disease in patients with elevated plasma cholesterol levels (>5.5 mmol/L). Prophylaxis with simvastatin is indicated if total cholesterol-serum concentration is 5.5 mmol/L (212 mg/dl) or higher, despite lipid-lowering diet and other non-pharmacological measures and should be carried out in conjunction with diet and other non-pharmacological measures (e.g., physical training and weight reduction).

C. Basis for Approvability or Not-Approval Recommendation

This application may be approved (AP) from a CMC viewpoint. This recommendation is based upon the evaluation of the relevant drug product manufacturing, characterization and stability data provided in this 505(b)(2) application. These data are substantial, detailed and acceptable. The applicant has demonstrated lot-to-lot consistency in the manufacture and quality of the drug product.

III. Administrative

A. Reviewer’s Signature

John C. Hill, Ph.D., Review Chemist: Same date as electronic review

B. Endorsement Block

Blair A. Fraser, Ph.D., Branch Chief: Same date as electronic review

C. CC Block

Margaret A Simoneau, RPH, Project Manager: Same date as electronic review
DMF: 18384  DMF Type:II
TITLE:Simvastatin

1. CHEM REVIEW No. 2
2. REVIEW DATE: 03-MAY-2006

3. ITEM REVIEWED:
   A. IDENTIFICATION
      USAN: Simvastatin
      Ingredient Dictionary name: Simvastatin
      Trade name:
      Manufacturer's code: SVT
      Chemical name:

      \[1S-[1\alpha,3\alpha,7\beta,8\beta(2S^*,4S^*),8\alpha\beta]]\]

      2,2-dimethyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenylester,
      \[1S-[1\alpha,3\alpha,7\beta,8\beta(2S^*,4S^*),8\alpha\beta]]\]

      CAS number, if available: [79902-63-9]

   B. LOCATION IN DMF
   Type of Submission  Date of Submission   Location of Information
   Amendment 001       23-MAR-2006          Volume 1.1

4. PREVIOUS DOCUMENTS
   Type of Document  Date of Document  Location  Description
   Original Submission  21-JUN-2005  Volume 1.1  Original Submission

5.  NAME & ADDRESS OF DMF HOLDER AND REPRESENTATIVE(S):
   NAME: Synthon BV
   Dr. Ing. H. M. Hultman

   ADDRESS:
   Microweg 22
   6545 CM Nijmegen
   The Netherlands
   Tel: +31 (0) 24 3727700; Fax: +31 (0) 24 3727739

   REPRESENTATIVE or U.S. AGENT (if applicable):
   NAME: Synthon Pharmaceuticals Inc.
ADDRESS: 9000 Development Drive  
P.O. Box 110487  
Research Triangle Park, NC 27709

CONTACT PERSON'S NAME, TITLE, DEPARTMENT: Kamali Chance, MPH,  
Ph.D., RAC  
ADDRESS: As noted above

TELEPHONE NUMBER: 919 493-6006  
FAX NUMBER: 919 493-6104

6. **DMF REFERENCED FOR:**  
NDA\ANDA\AADA\IND: NDA 21-961  
PRIMARY DMF (as needed)  
APPLICANT NAME: Synthon Pharmaceuticals Ltd.  
LOA DATE: 08-JUL-2005  
DRUG PRODUCT NAME: Simvastatin  
DOSAGE FORM: Tablet  
CODE:  
ROUTE OF ADMINISTRATION: Oral  
CODE:  
STRENGTH: 10, 20, 40 and 80 mg orally disintegrating tablets

7. **SUPPORTING DOCUMENTS:**  
NA

8. **CURRENT STATUS OF DMF:**  
DATE OF LAST UPDATE OF DMF: 23-MAR-2006  
DATE OF MOST RECENT LIST OF COMPANIES FOR WHICH LOA's HAVE BEEN PROVIDED: 19-JUL-2005

9. **CONSULTS:**  
NA

10. **COMMENTS:** The DMF holder has adequately addressed the deficiencies communicated 23-FEB-2006.

11. **CONCLUSION/RECOMMENDATION:** Acceptable
cc: DMF 18384
ONDQA/Valerie Jimenez
HFD-510/Division File NDA 21-961
HFD-510/Hillj/BFraser/PSimoneau

Appears This Way
On Original
3 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

_____ Draft Labeling (b4)

_____ Draft Labeling (b5)

_____ Deliberative Process (b5)
NDA 21-961

Simvastatin

Synthon

John C. Hill, Ph.D.
ONDQA/DPA I/DMMP/HFD-510

Chemistry Review #2

Appears This Way
On Original
# Table of Contents

**Table of Contents** ................................................................................................. 2

**Chemistry Review Data Sheet** ............................................................................. 3

**The Executive Summary** .................................................................................... 7

I. Recommendations ................................................................................................ 7
   A. Recommendation and Conclusion on Approvability ........................................... 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ......................................... 7

II. Summary of Chemistry Assessments .................................................................. 7
   A. Description of the Drug Product(s) and Drug Substance(s) ............................... 7
   B. Description of How the Drug Product is Intended to be Used .......................... 9
   C. Basis for Approvability or Not-Approval Recommendation ......................... 9

III. Administrative ..................................................................................................... 10
    A. Reviewer’s Signature .......................................................................................... 10
    B. Endorsement Block ............................................................................................ 10
    C. CC Block ........................................................................................................... 10

**Chemistry Assessment** ....................................................................................... 11

---

*Appears This Way On Original*
Chemistry Review Data Sheet

1. NDA # 21-961

2. REVIEW # 2

3. REVIEW DATE: 03-May-2006

4. REVIEWER: John C. Hill, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC Amendment</td>
<td>03-FEB-2006</td>
</tr>
<tr>
<td>BC Amendment</td>
<td>09-FEB-2006</td>
</tr>
<tr>
<td>BL Amendment</td>
<td>23-FEB-2006</td>
</tr>
<tr>
<td>C Amendment (DMF Correspondence)</td>
<td>27-MAR-2006</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

Name: Synthon Pharmaceuticals, Inc.
9000 Development Drive
P.O. Box 110487
Research Triangle Park, North Carolina 27709

Address: Kamali Chance, MPH, Ph.D. RAC, Director Regulatory Affairs

Representative: 919-493-6066

Telephone:

8. DRUG PRODUCT NAME/CODE/TYPPE:
a) Proprietary Name:
b) Non-Proprietary Name (USAN): Simvastatin
c) Code Name/# (ONDC only):
d) Chem. Type/Submission Priority (ONDC only):
   • Chem. Type: 3
   • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(2)
   Listed Drug: Zocor (Merck) NDA #19-766

10. PHARMACOL. CATEGORY: Hypercholesterolemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, dysbeta lipoproteinemia.

11. DOSAGE FORM: Tablet

12. STRENGTH/POTENCY: 10, 20, 40, and 80 mg

13. ROUTE OF ADMINISTRATION: Oral

14. Rx/OTC DISPENSED:   X  Rx    OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   ___X___Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   Name: Simvastatin

   Molecular Formula: C_{25}H_{38}O_{5}

   Molecular Weight: 418.57
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS1</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>18384</td>
<td>II</td>
<td>Synthon BV</td>
<td>Simvastatin API</td>
<td>4</td>
<td>Adequate</td>
<td>08-FEB-2006</td>
<td>LOA 08-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13-JAN-2006</td>
<td>LOA 27-MAY-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30-AUG-2005</td>
<td>LOA 11-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>Acceptable as NF</td>
<td>LOA 23-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>21-SEP-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-JAN-2003</td>
<td>LOA 28-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-AUG-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>30-AUG-2001</td>
<td>LOA 27-JUN-2005</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – 
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIND</td>
<td>70,964</td>
<td>Simvastatin Orally Disintegrating Tablets 10 mg, 20 mg, 40 mg,</td>
</tr>
</tbody>
</table>
18. STATUS:

### ONDC:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Acceptable</td>
<td>22-DEC-2005</td>
<td>John C. Hill, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### OGD:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only)

The application submission(s) covered by this review was taken in the date order of receipt.  
____ Yes  
____ No  
If no, explain reason(s) below:

Appears This Way  
On Original
The Chemistry Review for NDA 21-961

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC viewpoint this NDA is approvable (AE). The outstanding issue is:

1.) Acceptable CGMP status for pending pre-approval establishment inspections.

Based on the provided real-time and accelerated stability data, the proposed expiry period of 18 months is granted.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

1.) Synthon agrees to place —— batch of each strength on stability per stability protocols provided in Volume 5, Module 3, Section 2.P.8.2, Exhibits 1,3,5 and 7 each year, if manufactured. The results from the ongoing stability studies will be provided to the Agency in the annual reports.

2.) Synthon agrees to place the manufacturing process validation batches on stability per the bracketing schedule outlined in Volume 11, Module 3, Section 2.P.8.2, Exhibit 6.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1. Drug Product

The drug product presented in this NDA is an orally disintegrating tablet containing either 10, 20, 40 or 80 mg of simvastatin. The tablets are round, biconvex with the product strength debossed on one side and "ODT" on the other side. Following is a detailed description of appearance for each tablet strength.

10 mg Tablets
Yellow, round, biconvex tablets. These tablets are debossed with "S10" on one side and "ODT" on the other side.

20 mg Tablets
Peach, round, biconvex tablets. These tablets are debossed with "S20" on one side and "ODT" on the other side.
40 mg Tablets
Pink, round, biconvex tablets. These tablets are debossed with "S40" on one side and "ODT" on the other side.

80 mg Tablets
White to off-white, round, biconvex tablets. These tablets are debossed with "S80" on one side and "ODT" on the other side.

The individual components used to manufacture Simvastatin 10 mg, 20 mg, 40 mg and 80 mg orally disintegrating tablets are listed in the following table.

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Function</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin</td>
<td>lipidd altering agent</td>
<td>USP / Ph. Eur.</td>
</tr>
<tr>
<td>Butylated hydroxypropylcellulose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Povidone</td>
<td></td>
<td>USP</td>
</tr>
<tr>
<td>Crospovidone</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Hydroxypropylcellulose*</td>
<td></td>
<td>USP / NF</td>
</tr>
<tr>
<td>Silicified microcrystalline cellulose*</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Mint menthol*</td>
<td></td>
<td>in house</td>
</tr>
<tr>
<td>Sucrose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide red</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Glyceryl behenate*</td>
<td></td>
<td>NF</td>
</tr>
</tbody>
</table>

Excipients used to manufacture the drug product are of USP/NF quality with the exception of mint menthol and Silicified microcrystalline cellulose, which are tested in-house for quality. The drug product is composed b(4)

During formulation development of the drug product, careful evaluation of excipients, particle size and stability were conducted to develop a stable, rapidly disintegrating tablet. Initial formulation development, conducted with a simvastatin particle, provided fundamental information about interactions with excipients, development of a suitable optimization of parameters, evaluation of tablet size and forces on disintegration and dissolution times. The desire for increased bioavailability of simvastatin resulted in the use of a simvastatin particle. This formulation change required additional optimization of the and the formulations. Additionally, initial stability data indicated that basic excipients used in the formulation were resolved this stability issue.

2. Drug Substance:
The drug substance is simvastatin \{[1S-[1\alpha,3\alpha,7\beta,8\beta(2S*,4S*),8\alpha\beta)]\}. The manufacture of this compound is described in DMF# 18384. This DMF contains complete information on the manufacture, control of materials, control of critical steps and intermediates, process validation, manufacturing process development, elucidation of structure, impurities, control of the drug substance, drug substance specifications, analytical procedures, batch analyses, justification of specifications, reference standards and materials, release testing, container closure system, drug substance stability, and stability summary and conclusions.

Simvastatin is a lipid-lowering agent that is derived synthetically from lovastatin, a fermentation product of *Aspergillus terreus*. Simvastatin is an inactive lactone, which is hydrolyzed after ingestion to the corresponding beta-hydroxyacid. This main metabolite of simvastatin inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which catalyses an early step in the biosynthesis of cholesterol, limiting the rate of the total reaction.

Some of the key characteristics of Simvastatin drug substance that may influence the performance of the drug product, and were evaluated during product development include solubility, potential isomerism/polymorphism, exposure to light, alkaline media and oxidation. In order to increase the bioavailability, the simvastatin drug substance was mean particle size from around to around

B. Description of How the Drug Product is Intended to be Used

Hypercholesterolemia:

Simvastatin is used to reduce increased plasma total and LDL cholesterol in patients with primary hypercholesterolaemia (type IIa) or combined hyperlipidemia (type IIb) in combination with dietary measures when no adequate effect is obtained with dietary measures and other non-pharmacological measures alone (e.g., fitness training and weight loss).

Coronary Heart Disease:

Simvastatin is used for the secondary prevention of coronary heart disease in patients with elevated plasma cholesterol levels (>5.5 mmol/L). Prophylaxis with simvastatin is indicated if total cholesterol-serum concentration is 5.5 mmol/L (212 mg/dl) or higher, despite lipid-lowering diet and other non-pharmacological measures and should be carried out in conjunction with diet and other non-pharmacological measures (e.g., physical training and weight reduction).

C. Basis for Approvability or Not-Approval Recommendation
This application is approvable (AE) from a CMC viewpoint. This recommendation is based upon the evaluation of the relevant drug product manufacturing, characterization and stability data provided in this 505(b)(2) application. These data are substantial, detailed and acceptable. The applicant has demonstrated lot-to-lot consistency in the manufacture and quality of the drug product. However, certain CMC deficiencies remain be addressed. The CGMP facility inspections are pending.

III. Administrative

A. Reviewer's Signature

B. Endorsement Block

John C. Hill, Ph.D., Review Chemist: Same date as electronic review
Blair A. Fraser, Ph.D., Branch Chief: Same date as electronic review

C. CC Block

Margaret A Simoneau, RPH, Project Manager: Same date as electronic review

Appears This Way
On Original
4 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

John C. Hill
CHEMIST

Blair Fraser
CHEMIST

Appears This Way
On Original
NDA 21-961

Simvastatin

Synthon

John C. Hill, Ph.D.
ONDQA/DPA I/DMEP/HFD-510

Appears This Way
On Original
Table of Contents

Table of Contents .................................................................2
Chemistry Review Data Sheet .....................................................3
The Executive Summary ............................................................7
I. Recommendations .....................................................................7
   A. Recommendation and Conclusion on Approvability ..................7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
      Management Steps, if Approvable ........................................7
II. Summary of Chemistry Assessments .......................................7
    A. Description of the Drug Product(s) and Drug Substance(s) .......7
    B. Description of How the Drug Product is Intended to be Used ....9
    C. Basis for Approvability or Not-Approval Recommendation .....10
III. Administrative ......................................................................10
    A. Reviewer’s Signature ........................................................10
    B. Endorsement Block .........................................................10
    C. CC Block .......................................................................10
Chemistry Assessment ..............................................................11
   S DRUG SUBSTANCE [Simvastatin, ] (Acceptable) .....................11
   P DRUG PRODUCT [Name, Dosage form] (Acceptable) ................26
   A APPENDICES ..................................................................119
   R REGIONAL INFORMATION ..............................................119
II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 .............................121
    A. Labeling & Package Insert .................................................121
    B. Environmental Assessment Or Claim Of Categorical Exclusion ....123
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>18384</td>
<td>II</td>
<td>Synthon BV</td>
<td>Simvastatin API</td>
<td>4</td>
<td>Adequate</td>
<td>Pending Review</td>
<td>LOA 08-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>Pending Review</td>
<td>27-MAY-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>30-AUG-2005</td>
<td>LOA 11-JUL-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>Acceptable as NF</td>
<td>LOA 23-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>21-SEP-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-JAN-2003</td>
<td>LOA 28-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>01-AUG-2003</td>
<td>LOA 30-JUN-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acceptable</td>
<td>30-AUG-2001</td>
<td>LOA 27-JUN-2005</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – 
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIND</td>
<td>70,964</td>
<td>Simvastatin Orally Disintegrating Tablets 10 mg, 20 mg, 40 mg, and 80 mg.</td>
</tr>
</tbody>
</table>
18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Pending</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPDRA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Acceptable</td>
<td>22-DEC-2005</td>
<td>John C. Hill, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only)

The application submission(s) covered by this review was taken in the date order of receipt.  

[ ] Yes  [ ] No  
If no, explain reason(s) below:

Appears This Way  
On Original
The Chemistry Review for NDA 21-961

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a CMC viewpoint this NDA is approvable (AE). The outstanding issues are:

1.) Acceptable responses to CMC review deficiencies,
2.) Acceptable CGMP status for pending pre-approval establishment inspections.
3.) Acceptable status of outstanding DMF reviews.

Based on the provided real-time and accelerated stability data, the proposed expiry period of 18 months is granted.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

1.) Synthon agrees to place each batch of each strength on stability per stability protocols provided in Volume 5, Module 3, Section 2.P.8.2, Exhibits 1, 3, 5 and 7 each year, if manufactured. The results from the ongoing stability studies will be provided to the Agency in the annual reports.

2.) Synthon agrees to place the manufacturing process validation batches on stability per the bracketing schedule outlined in Volume 11, Module 3, Section 2.P.8.2, Exhibit 6.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1. Drug Product

The drug product presented in this NDA is an orally disintegrating tablet containing either 10, 20, 40 or 80 mg of simvastatin. The tablets are round, biconvex with the product strength debossed on one side and "ODT" on the other side. Following is a detailed description of appearance for each tablet strength.

10 mg Tablets
Yellow, round, biconvex tablets. These tablets are debossed with "S10" on one side and "ODT" on the other side.

20 mg Tablets
Peach, round, biconvex tablets. These tablets are debossed with "S20" on one side and "ODT" on the other side.

40 mg Tablets
Pink, round, biconvex tablets. These tablets are debossed with "S40" on one side and "ODT" on the other side.

80 mg Tablets
White to off-white, round, biconvex tablets. These tablets are debossed with "S80" on one side and "ODT" on the other side.

The individual components used to manufacture Simvastatin 10 mg, 20 mg, 40 mg and 80 mg orally disintegrating tablets are listed in the following table.

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Function</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simvastatin</td>
<td>Lipid altering agent</td>
<td>USP / Ph. Eur.</td>
</tr>
<tr>
<td>Bucryl hydroxypropylcellulose*</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Povidone</td>
<td></td>
<td>USP</td>
</tr>
<tr>
<td>Crospovidone</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Silicified microcrystalline cellulose*</td>
<td>In house</td>
<td>USP / NF</td>
</tr>
<tr>
<td>Mint menthol*</td>
<td>In house</td>
<td></td>
</tr>
<tr>
<td>Sucrose</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Iron oxide red</td>
<td></td>
<td>NF</td>
</tr>
<tr>
<td>Glyceryl behenate*</td>
<td></td>
<td>NF</td>
</tr>
</tbody>
</table>

Excipients used to manufacture the drug product are of USP/NF quality with the exception of mint menthol and Silicified microcrystalline cellulose, which are tested in-house for quality. The drug product is composed of the

During formulation development of the drug product, careful evaluation of excipients, particle size, and stability were conducted to develop a stable, rapidly disintegrating tablet. Initial formulation development, conducted with a simvastatin particle, provided fundamental information about interactions with excipients, development of a suitable, optimization of parameters, evaluation of tablet size and forces on disintegration and dissolution times. The desire for increased bioavailability of simvastatin resulted in the use of a simvastatin particle. This formulation change required additional optimization of the and the formulations. Additionally, initial stability data indicated that basic excipients used in the formulation of simvastatin on stability.
2. Drug Substance:

The drug substance is simvastatin \{[1S-[1\alpha,3\alpha,7\beta,8\beta(2S*,4S*),8\alpha\beta]]}\textsuperscript{b(4)}

The manufacture of this compound is described in DMF# 18384. This DMF contains complete information on the manufacture, control of materials, control of critical steps and intermediates, process validation, manufacturing process development, elucidation of structure, impurities, control of the drug substance, drug substance specifications, analytical procedures, batch analyses, justification of specifications, reference standards and materials, release testing, container closure system, drug substance stability, and stability summary and conclusions.

Simvastatin is a lipid-lowering agent that is derived synthetically from lovastatin, a fermentation product of \textit{Aspergillus terreus}. Simvastatin is an inactive lactone, which is hydrolyzed after ingestion to the corresponding beta-hydroxyacid. This main metabolite of simvastatin inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which catalyses an early step in the biosynthesis of cholesterol, limiting the rate of the total reaction.

Some of the key characteristics of Simvastatin drug substance that may influence the performance of the drug product, and were evaluated during product development include solubility, potential isomerism/polymorphism, exposure to light, alkaline media and oxidation. In order to increase the bioavailability, the simvastatin drug substance was \textsuperscript{b(4)}mean particle size from around \textsuperscript{b(4)}to around \textsuperscript{b(4)}

B. Description of How the Drug Product is Intended to be Used

\textbf{Hypercholesterolemia:}

Simvastatin is used to reduce increased plasma total and LDL cholesterol in patients with primary hypercholesterolaemia (type IIa) or combined hyperlipidemia (type IIb) in combination with dietary measures when no adequate effect is obtained with dietary measures and other non-pharmacological measures alone (e.g., fitness training and weight loss).

\textbf{Coronary Heart Disease:}

Simvastatin is used for the secondary prevention of coronary heart disease in patients with elevated plasma cholesterol levels (>5.5 mmol/L). Prophylaxis with simvastatin is indicated if total cholesterol-serum concentration is 5.5 mmol/L (212 mg/dl) or higher, despite lipid-lowering diet and other non-pharmacological measures and should be carried out in conjunction with diet and other non-pharmacological measures (e.g., physical training and weight reduction).
C. Basis for Approvability or Not-Approval Recommendation

This application is approvable (AE) from a CMC viewpoint. This recommendation is based upon the evaluation of the relevant drug product manufacturing, characterization and stability data provided in this 505(b)(2) application. These data are substantial, detailed and acceptable. The applicant has demonstrated lot-to-lot consistency in the manufacture and quality of the drug product. However, certain CMC deficiencies remain be addressed. The CGMP facility inspections are pending.

III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

John C. Hill, Ph.D., Review Chemist: Same date as electronic review
Blair A. Fraser, Ph.D., Branch Chief: Same date as electronic review

C. CC Block

Margaret A Simoneau, RPH, Project Manager: Same date as electronic review

Appears This Way On Original
113 Page(s) Withheld

✓ Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

John C. Hill
1/3/2006 11:09:30 AM
CHEMIST

Blair Fraser
1/3/2006 12:56:39 PM
CHEMIST

Appears This Way
On Original